DIGITAL.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/430825
Datos de investigación
Set de datos (Dataset)
Supplementary information for a site-specific MiniAp4-trastuzumab conjugate prevents brain metastasis
1H and 13C NMR spectra of 3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid; UPLC and MS data of DBM-Ang2 and DBM-miniAp4; Mw and isoelectric point of peptides and mAb conjugates; cell cycle arrest data of SKBR-3, BT-474, or MDA-MB-231 cells treated with Tz, Tz-Ang2, and Tz-MiniAp4; MS characterization of AF647-modified Tz, Tz-Ang2, and Tz-MiniAp4; confocal images of BT-474 cells incubated with Tz, Tz-Ang2, and Tz-MiniAp4; mass characterization of Tz, Tz-Ang2, and Tz-MiniAp4 after immunoprecipitation of the acceptor well from HBBBCMTA; stability of Ang2 and MiniAp-4 in mouse serum; quantification of NIR fluorescence each mouse injected with Tz, Tz-Ang2, and Tz-MiniAp4; and data related to organotypic cultures treated with Tz and Tz-MiniAp4, Monoclonal antibodies (mAbs) are changing cancer treatments. However, the presence of the blood–brain barrier (BBB) and the blood–tumor barrier (BTB) limits the use of mAbs to treat brain cancer or brain metastasis. Molecules that hijack endogenous transport mechanisms on the brain endothelium (brain shuttles) have been shown to increase the transport of large molecules and nanoparticles across the BBB. Among these shuttles, protease-resistant peptides such as MiniAp-4 are particularly efficient. Here, we report the synthesis, characterization, and evaluation of site-specific mAb–brainshuttle antibody conjugates (ASC) based on the anti-HER2 mAb trastuzumab (Tz) and four molecules of MiniAp-4. The ASCs preserve the binding and cell cycle arrest capacity of Tz. MiniAp-4 ASC displays enhanced transport across an in vitro BBB cellular model with respect to Tz and Tz conjugated to Angiopep-2, the brain shuttle that has advanced the most in clinical trials. More importantly, evaluation of Tz-MiniAp4 in a murine brain metastasis model demonstrated that the protease-resistant peptide showed preferential transport across the BBB/BTB, displaying a marked therapeutic effect and protecting against metastasis development. The technology described herein could be applied to any antibody of interest to treat central nervous system-related diseases. MiniAp-4 enhances the brain transport of the monoclonal antibody trastuzumab, preventing brain metastasis., Peer reviewed
DOI: http://hdl.handle.net/10261/430825
DIGITAL.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/430825
HANDLE: http://hdl.handle.net/10261/430825
DIGITAL.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/430825
PMID: http://hdl.handle.net/10261/430825
DIGITAL.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/430825
Ver en: http://hdl.handle.net/10261/430825
DIGITAL.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/430825